EGFR and non-small cell lung carcinoma: For example, EGFR tyrosine kinase inhibitors (such as gefitinib and erlotinib) can significantly prolong the progression-free survival of patients with EGFR-mutated non-small cell lung cancer (NSCLC), thus becoming one of the first-line treatment options [77].